SGLTi Therapy Decreases Long-Term CVD and End-Stage Kidney Disease Risk in Type 1 Diabetes - The Cardiology Advisor

A study was conducted to determine if SGLT2 inhibitors decrease risk for end-stage kidney disease or cardiovascular disease in patients with type 1 diabetes.

Among patients with type 1 diabetes, sodium-glucose cotransporter inhibitor (SGLTi) therapy reduced risk for cardiovascular disease (CVD) and end-stage kidney disease (ESKD), especially among patient… [+2920 chars]

full article...